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A seventy five percent increase in cancer incidence within 10 years is one of 
the major human health issues based on the World Health Organization 
(WHO) evaluation. Prevention of cancer through health screening was sug-
gested by the WHO as a means of early detection of cancer. Thymidine kinase 
1 (TK1) is one of the key enzymes for DNA replication and cell division, 
which could have a role in tumor formation and progression. Exosomes are 
extracellular vesicles which were recently shown to act as messengers of tu-
mor cells to communicate with cells in the body. The aim of this study was 
to evaluate if TK1 was excreted via exosomes in a BJ tumor (BJ-T) cell line 
as well as BJ normal (BJ-N) cell line. Exosomes were isolated from media 
supernatants of BJ-T and BJ-N cells using ultracentrifugation and the final 
exosome preparations were resuspended in phosphate buffered saline. TK1 
activity and concentration in the supernatants before and after ultracentrifu-
gation as well as exosome samples were evaluated by [3H]-dThd phosphory-
lation assay and dot-blot chemiluminescence assay, respectively. Specific ac-
tivity of BJ-T exosome-derived TK1 was 16.9 times more than BJ-N exo-
some-derived TK1, where there was also two times more TK1 concentration 
in BJ-T exosomes compared to BJ-N exosomes. In conclusion, TK1 excretion 
was via exosomes and exosome-derived TK1 could be a tumor biomarker for 
BJ-T cells. Furthermore in vitro and in vivo investigations are needed in order 
to evaluate whether TK1 could be a useful biomarker for tumor tissue and/or 
in clinical level. 
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Abstract 
 
 
“If you have your health, if you have people in your life 
to love, you are blessed. Slow down and enjoy the sim-
ple things in life.” 
Joel Osteen 
 
 
To my best family ever 
To my devoted husband 
To my beloved “Bah”  
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Here is the meaning of used abbreviations and technical terms in this study. 
 
Abbreviation Stands for/meaning 
  
CAF 
CPM 
Cancer associated fibroblast 
Count per minute 
DC Dendritic cells 
DMEM Dulbecco’s Modified Eagle’s Medium 
DT Doubling time 
FBS Fetal Bovine Serum 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
MMP6 Matrix metallopeptidase 6 
MVBs Multivesicular bodies 
NC Nitrocellulose  
NSCLC non-small-cell lung carcinoma  
NT Nucleoside transport 
PCNA Proliferating cell nuclear antigen 
PVDF Polyvinylidene difluoride 
SDS-PAGE Sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
STK1 Serum thymidine kinase 1 
TBS tris-buffered saline 
TBST Tween 20 + tris-buffered saline 
TDP Thymidine diphosphate 
TK1 Thymidine kinase 1 
TMP Thymidine monophosphate 
TMPK Thymidine monophosphate kinase 
TTP Thymidine triphosphate 
WHO World Health Organization 
 
Abbreviations 
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1.1 Cancer 
Cancer is the second leading cause of human death worldwide, approximately 9.6 
million deaths in 2018 based on the World Health Organization (WHO). The etiol-
ogy of cancer is not well understood, and factors like poor diet, infections, risky 
behavioral etc, can increase the cancer risk. The WHO reports show increasing num-
bers of death due to cancer compared to previous years (1). Today, different cancer 
treatments are available depending on various factors such as the cancer type and 
cancer stage. The treatment can be one step or multiple steps (combined therapy) 
(2). Lots of scientific centers, laboratories and universities work and collaborate to 
research cancer biology, including prospective cancer drugs and the treatment 
routes. Biologically at the molecular level, alterations in genetic and epigenetic char-
acteristics of the cells are the leading causes of cancer. Although cells can repair 
themselves in different ways, some errors still remain and cause uncontrolled pro-
liferation, apoptosis inhibition, cell migration and invasion (3). 
 
1.2 Cell communication 
Cells need to communicate with each other to be alive. Cell communication is 
needed to sustain individual cells as well as to work with other cells as a group, a 
tissue, an organ and the organism. Cell signaling as the method of communication 
can be between closely related neighboring cells and/or more distant cells. Extracel-
lular signals transduce via internal/external receptors and different sets of intracel-
lular signaling proteins and cells respond in different ways, which could be a short 
term response such as changing in metabolism, contraction or secretion, or a long 
term response such as gene expression, growth and death (4,5). 
 
1.3 Protein secretion approaches 
Exporting extra cellular components is one way to communicate. Cells can com-
municate not only by cell-cell connections but also by secreted messengers (6). 
1 Introduction 
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There are two major cellular secretion routes: classical secretion and non-classical 
secretion. The classical route is started from ribosomes which make the primary 
proteins and the newly synthesized proteins pass through the endoplasmic reticulum 
and Golgi apparatus for modification and packaging into secretory vesicles, and fi-
nally the proteins are excreted via exocytosis (7). The non-classical secretion con-
sists of four routes: 1) direct translocation of proteins across membranes 2) blebbing 
3) lysosomal secretion and 4) secretion by exosomes derived from multivesicular 
bodies (MVBs). Multivesicular bodies are one of the subsets of endosomes which 
are used not only for degradation of cytoplasmic protein by fusion to lysosomes but 
they can also fuse to the cytoplasmic membrane and release the exosome into the 
extracellular space (8). 
 
1.4 Exosomes and their role in cell communication 
The extracellular vesicles can be classified 
into three major groups based on their struc-
ture: apoptotic bodies, microvesicles and ex-
osomes. Extravesicular vesicles size can be 
in the range of 40-2,000 nm. Exosomes are 
bilayer vesicles derived from endolysosomal 
pathway, which can be 40-120 nm in size 
and are secreted by various cells (9). Alt-
hough exosomes can be isolated from serum, 
body fluid and tissue culture media, most ap-
proaches to isolate them in research is done via isolation from supernatants of cul-
tured serum-free cell media (6,10). All cells in multicellular organisms need to com-
municate via the microenvironment and also communicate with distant cells in order 
to maintain homeostasis. Exosomes carry different types of molecules like proteins 
and different RNAs, which can act as signaling molecules.  Some proteins are ex-
osome specific and present in almost all exosomes, and therefore they are used as 
general exosome markers (like CD9, CD63 and CD81). The exosomal protein con-
tent can vary depending on the exosome’s prospective roles and functions. They can 
contain proteins which have roles in membrane trafficking like annexins, or they 
can have enzymes like glyceraldehyde 3-phosphate dehydrogenase (GAPDH). They 
can also carry adhesion proteins on their membranes such as various integrins. The 
fate of exosomes and their function is partially based on their content (internal 
mRNA and miRNA, and membrane proteins) (11).  Exosomes as a communication 
tool can also be like a double-edged sword. On one hand, they can keep normal cells 
in touch, act as an antigen-presenting vesicles as well as induce antitumor immune 
responses, but on the other hand, they can also keep cancer cells in touch and pro-
mote their capability to progress by induction of cancer cell migration, angiogenesis, 
Figure 1. Some of known proteins and pro-
tein markers in the exosome. 
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immune inactivation and immune suppression, which will be described in more de-
tail in section 2.5 (6,9). 
 
1.5 BJ - Tumor cells, BJ - Normal cells and cancer-associ-
ated fibroblasts (CAF) 
BJ-N cell is a foreskin human derived fibroblast, which is mostly used for stable 
transfection studies (12) and as a control for its tumor version (BJ-T). BJ-T cells 
were immortalized via human telomerase reverse transcriptase. There are other can-
cer-associated fibroblasts which are present in different types of cancer. Fibroblasts 
are able to make tumors by themselves but can also be altered as CAFs and promote 
tumorigenic features like facilitating tumor migration and invasion via angiogenesis, 
modifying the microenvironment (13). Thus, studying BJ-T cells can reveal some 
information regarding both fibroblast tumors and other tumor microenvironments. 
 
1.6 Thymidine kinase 1; Molecular structure and enzymatic 
activity  
Thymidine kinase (TK) is 
a type of kinase in human 
and animal cells. There are 
two isoforms of TK de-
tected in animal cells: TK1 
mostly in the cytoplasm 
and TK2 in the mitochon-
dria (14). TK1 adds a 
phosphate group to thymidine to make it ready for the rest of deoxythymidine tri-
phosphate (dTTP) synthesis, which is essential for DNA and cell proliferation (15). 
The activity of TK1 is higher in proliferating cells and reaches its highest level at 
the G1 phase/S-phase of the cell cycle and it decreases in the M phase (16). It can 
exist as a monomer with almost no function or act as a dimer, which has low activity 
or even a tetramer with the highest activity and a molecular weight of  around 
100kDa (15). Two pathways can provide nucleotides for DNA synthesis: the de 
novo pathway and the salvage pathway. The salvage pathway reuses the degraded 
DNA as a source of deoxyribonucleosides (dNs) while low molecule weight precur-
sors are used in the de novo pathway (17). Figure 2 shows part of the salvage path-
way in which TK1 has a role. Thymidine is imported into the cells by nucleoside 
transporters (NT) and then TK1 has a role in cytoplasm to make thymidine mono-
phosphate from it (18). 
Figure 2. Thymidine kinase 1 role in dTTP synthesis. 
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2.1 TK1 and related diseases 
Different mutations in genes could make a malfunction protein or even skip the pro-
tein synthesis which leads to deficiency. It is known that mutations in the TK2 gene 
results in mitochondrial DNA depletion syndrome (myopathic form), but there is no 
known disease caused by TK1 deficiency (19). Although TK1 deficiency does not 
cause disease, there are some types of cancers (lung, liver, cervix) which were 
proved their association with TK1 elevation in terms of tumor growth rate (20). It is 
also shown that the thymidine kinase knockout mice (KO) has shorter life span than 
the normal mice which may due to kidney sclerosis and KO mice has different sali-
vary gland secretions, elevated level of serum thymidine and significantly lower 
spleen lymphocyte cloning which changes the histological lymphoid pattern of 
spleen and all these shows abnormal immune system(21). Moreover, all diseases 
which cause cell proliferation such as inflammation could lead to TK1 elevation 
(17). Chen Z. and colleagues found out that by screening serum TK1 (STK1) in 
11,880 persons that 83% of STK1-positive persons had various diseases from hep-
atitis and helicobacter pylori-positive to benign and malignant cancers. They pin-
pointed that more than 2 pM STK1 could be an indicator for the future malignancies 
occurrence (22). Particularly, it was shown that STK associates with different pa-
rameters in heamatological cancers such as the clinical stage and the tumor burden 
(17). There are also some studies were done on serum TK and its role in solid can-
cers and a review summarized them. It showed that STK has the statistically corre-
lation with breast cancer stage and the total tumor TK concentration is significantly 
higher in the recurrent cases than the non-recurrent ones. It was revealed that there 
is a significant difference between STK level of the metastatic colorectal cancer pa-
tients and the normal controls. In addition, investigation in the lung cancer eluci-
dated STK role as a prognostic marker for the non-small-cell lung carcinoma 
(NSCLC) (23). 
 
2 Literature Review 
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2.2 TK1 in normal and cancer cells 
TK1 activity increases in the G1 phase and reaches its highest level at the G1 
phase/S-phase of the cell cycle where after it decreases in the M phase in normal 
cells while in the cancer cells, TK1 levels can still be high in the M phase and G2 
phase (24,25). Several studies have been performed based on serum TK1 and TK1 
in cell lines but fewer studies have been done on cell surface TK1. Weagel EG. and 
colleagues indicate that TK1 is upregulated in Burkitt’s lymphoma and different 
types of leukemia based on evaluating cell-surface TK1 in cell lines and patients 
tumor samples (26). These authors also studied lung, breast and colorectal cancer 
cell lines and cell-surface TK1. They found that there was significantly higher cell-
surface TK1 in all cell lines (except one colorectal cell line) than controls. Further-
more, they compared the TCGA data with their study and revealed that TK1 gene 
expression was upregulated in cancer patients compared to the healthy individuals 
(27). Xiaofei Wang and Richard Wahl also worked on doubling time (DT) in breast 
and colorectal cancer cell lines and its correlation with TK1. They found that TK1 
had a better correlation with DT than the conventional proliferation markers such as 
Ki67 and PCNA. Here, they observed a shorter DT with higher amount of TK1 
(28,29). 
 
2.3 TK1 as a biomarker in cancers  
TK1 as an initial enzyme for preparing TTP has a critical role in DNA replication, 
DNA repair process and cell proliferation. DNA repair and replication pathways are 
two approaches which are studied in cancer. He and colleagues used chemo-lumi-
nescent dot assays and immunohistochemistry (IHC) for TK1 level evaluation in 
serum and tissues where they found that TK1 tissue expression correlated to the 
pathological stage and the clinical grade, remission and relapse of lung cancer, oe-
sophagus cancer and one type of breast cancer (30,31). One the first studies which 
was done on serum thymidine kinase role as a prognostic marker was Gronowitz 
study on non-Hodgkin's lymphoma patients which showed that STK1 increases dur-
ing the progression of disease, decreases in the case of successful therapy and again 
increasing in the case of cancer relapse (32). Focusing on breast cancer, Nisman and 
his colleagues performed a study on serum TK1 activity. Using quantitative ELISA, 
serum levels of TK1 in breast cancer patients was significantly higher than the nor-
mal persons, which suggests that it could be an important prognostic factor in terms 
of recurrence-free survival in breast cancer (33). Additionally, the Human Protein 
Atlas shows that lower expression of TK1 is a prognostic marker in different cancers 
like liver, lung and renal (34). A meta-analysis study was done in 2013 and fifteen 
studies were evaluated by details which were selected among 453 studies. It showed 
that individually TK1 was not a significant diagnostic biomarker. However, TK1 
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was a significant marker with combination of other biomarkers and using TK1 with 
other biomarkers was preferred in order to increase the specificity (35). The initial 
idea was that TK1 could be either secreted out of the cells, could be inside the cells 
and localizing at the cytoplasm or mitochondria, whereas a study also showed that 
it could locate on the cell surface membrane and therefore it could have a role in 
invasiveness and cell migration in the lung cancer cell line (36). Moreover, surface 
TK1 is significantly higher in the breast and colorectal cancer cell lines and also 
higher in cancer patient tissues compared to normal tissues, which shows the rele-
vance of the clinical evidence and the cancer cell lines results (27). Evita’s study on 
lymphoma and leukemia also showed that TK1 which was located on the cell mem-
brane could be a possible target for immunotherapy in haematological cancers (26). 
2.4 Extracellular vesicle trafficking in cancer 
As previously mentioned, extracellular vesicles including exosomes have roles in 
cell communication and homeostasis of the microenvironment. A research group 
working on glioblastoma exosomes found that the RNA content of exosomes could 
act as a messenger for distant cells, and these RNAs could be translated in the target 
cells. They also indicated that glioblastoma exosomes could induce proliferation in 
the human glioma cell line (37). Safaei and her colleagues worked on drug resistance 
ovarian carcinoma cells with cisplatin (CDDP) as a chemotherapy drug. They con-
cluded that cancer cells could organise the CDDP transporters into the exosomal 
pathway and escape the cisplatin treatment by exporting CDDP out of the cells, sug-
gesting alteration of extracellular vesicular trafficking resulting in drug resistance 
(38). In a recent review, the different roles of extracellular vesicles in different can-
cers were discussed. One of the cancer hallmarks is angiogenesis and several studies 
showed that extracellular vesicles including exosomes could carry pro-angiogenic 
factors and stimulate the endothelial cells for angiogenesis and tumor growth (39). 
Extracellular vesicles can also make the proper microenvironment for fibroblasts 
surrounding the cancer cells to be resistant to apoptosis and consequently fibroblasts 
can ease the migration and invasion of the cancer cells (40). There are many studies 
focusing on extracellular microvesicles and their roles in most of the cancer hall-
marks including evading the immune response, facilitating invasion and migration 
of tumor cells and multi-drug resistance (41). 
2.5 Exosomes in normal cells and cancer cells 
Different normal cell types in the human body such as endothelial cells, blood cells 
and platelets are able to excrete exosomes for a variety of reasons. Wieckowski and 
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Whiteside compared the tumor-derived exosomes and dendritic cell (DC)-derived 
exosome (as normal cells) and found that their contents and functions were different. 
DC-derived exosomes stimulated T-cell proliferation whereas the tumor-derived ex-
osomes induced T-cells apoptosis that stopped the immune response against tumor 
cells (41). Exosomes could also induce metastasis and angiogenesis in lung cancer 
cells. They utilized different lung cancer cell lines and also an in vivo metastasis 
model showing that platelet-derived exosomes could induce proliferation in the 
A549 cell line via upregulating cyclin D2 expression in addition to upregulating 
MMP-6 and some growth factors as angiogenic factors. Furthermore, in a lung can-
cer mice model, the exosomes resulted in more metastatic foci not only in the lungs 
but also in the bone marrow (39). Webber and colleagues even tried to evaluate how 
different tumor-derived exosomes could act on the normal cells. Here, they used a 
mesothelioma cell line, different prostate cancer cell lines, a bladder cancer cell line, 
a colorectal cancer cell line and a breast cancer cell line. Fibroblasts were the normal 
cells, which were treated with different cancer cell lines exosomes. The results in-
dicated that tumor-derived exosomes regardless of the cancer type could increase 
expression of muscle actin and other proteins for differentiation of fibroblasts into 
myofibroblasts (42).  
2.6 Exosomes and TK1 relations in cancer 
There are only a few studies were done on the exosome-derived TK1 and its role in 
cancers. 
 Del Re and colleagues studied the correlation of plasma-derived exosomal TK1 
with the clinical response to cyclin-dependent kinase 4/6 inhibitors in breast cancer 
patients. They found that TK1 expression was statistically and significantly higher 
in cancer patients than the normal cases while there was no association between the 
baseline of TK1, CD4 and CD6. They claimed that exosome-derived TK1 could be 
a biomarker for early patient detection who could get the CD4/6 dependent treatment 
later (43). 
 In another study one class of exosomes named prostasomes which are excreted 
out of acinar and epithelial cells of the prostate gland were studied. They used sem-
inal fluid of healthy individuals from the university hospital (Uppsala, Sweden) and 
extracted the normal human prostasomes comparing them with the malignant cell 
line-derived exosomes (PC3, LNCaP and Du145). They found that TK1 activity was 
higher in the malignant prostate cell line exosomes than prostasomes of healthy in-
dividuals and concluded that exosome-derived TK1 could be a useful biomarker for 
not only monitoring but also during the prognosis of prostate cancer (44). 
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Although different studies were performed on the TK1 roles in different cancer cell 
lines and different cancer patients, the excretion route of TK1 as a basic biological 
feature has not been studied so far. The aim of this study was to deduce whether 
exosomes could be a candidate for carrying TK1 out of the cells, and if the amount 
of excreted TK1 in BJ-T cells is different from BJ-N cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Aim of Study 
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4.1 Cell lines and cell culture 
The BJ-N cells are human fibroblasts which can be immortalized via human te-
lomerase reverse transcriptase and makes BJ-T cells. These two cell lines were used 
in the current project. The normal fibroblast line was from a human child provided 
by Uppsala University Hospital (Cell code S0013). The cell lines were cultured in 
T175 flasks in DMEM media (Sigma-Aldrich) with 6.5% fetal bovine serum (FBS) 
as a low serum culturing condition to prevent false positive results due to serum 
TK1 level and 1% penicillin-streptomycin (Sigma-Aldrich) as an antibacterial and 
antifungal agent. Cells were incubated at 37 °C supplied with 5% CO2. The super-
natant was collected when the cells became confluent which was reached once a 
week for normal cells and twice a week for tumor cells. The normal cells grew 
slower than the tumor cells and took a longer time to reach the desired confluency. 
 
4.2 Exosome isolation 
A differential preparative ultracentrifuge-based technique was used for exosome 
isolation. Twenty-five ml of cell free supernatant media was collected from each 
culture flask. The exosome isolation was done in two steps: the normal centrifuga-
tion and the ultracentrifugation, where the whole process needed to be optimized. 
The normal centrifugation optimization was done using a Multifuge x3R (Ther-
mofisher) to get rid of free nuclei, free mitochondria and cell debris. The supernatant 
was subsequently collected without disturbing the pellets. This supernatant was then 
used for ultracentrifugation, which also needed to be optimized. This was done 
through three separate experiment with different normal centrifugation and ultra-
centrifugation settings as follows. In the first round, samples were centrifuged at 
10,000 x g for half an hour and then subjected to ultracentrifugation at 80,000 x g 
for 3 hours. The second round, normal centrifuge was run at 10,000 x g for an hour 
4 Materials and Methods 
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and ultracentrifugation was run at 96,000 x g for 5 hours, and in the last round the 
samples were run for 1 hour at 10,000 x g in the normal centrifuge followed by 6 
hours running at 107,000 x g in the ultracentrifuge (Table. 1). The resulting pellet 
was dissolved in 100 or 200 µl PBS for further investigation. The concentration 
factor was calculated for exosome samples based on the volume of supernatant me-
dia before ultracentrifugation and the volume of the prepared exosome sample after 
ultracentrifugation to make the results comparable. The samples in the optimizing 
part included BJ-T cell supernatant media before ultracentrifugation (OTBU), BJ-T 
cell supernatant media after ultracentrifugation (OTAU) and BJ-T exosomes 
(OTEX). 
 After optimizing the ultracentrifugation setting, the exosome isolation process 
was done on the BJ-T cell supernatant media and the BJ-N cell supernatant media 
at the same time to minimize the confounding elements. Therefore each sample set 
included tumor samples; BJ-T cell supernatant media before ultracentrifugation 
(TBU), BJ-T cell supernatant media after ultracentrifugation (TAU) and BJ-T exo-
some (TEX) and normal samples; BJ-N cell supernatant media before ultracentrifu-
gation (NBU), BJ-N cell supernatant media after ultracentrifugation (NAU) and BJ-
N exosome (NEX). 
 Additionally, the ultracentrifuge was set twice on 132,000 x g (maximum speed 
for the rotor) for 6 hours but due to technical issues, it stopped during both runs. 
Therefore, this setting was eliminated from further optimizing steps. 
 It has to be mentioned that no complementary technique (like electron micros-
copy or exosome specific antibody) has been used to examine the exosome isolation 
and purification accuracy while it’s believed that the pellet after ultracentrifugation 
is exosome pellet. 
 
Table 1. Centrifugation and ultracentrifugation optimizing settings for exosome isolation. 
 Centrifugation  Ultracentrifugation 
Setting Speed (x g) Time (Hour) Temp(°C) Speed (x g) Time (Hour) Temp.(°C) 
1 10000 0.5 4 °C 80,000 3 4 °C 
2 10000 1 4 °C 96,000 5 4 °C 
3 10000 1 4 °C 107,000 6 4 °C 
 
 
4.3 Protein quantification 
Protein quantification was measured on the exosome samples to evaluate the total 
exosome protein amounts in BJ-N exosome samples compared to BJ-T exosome 
samples. The supernatant media samples were not used for protein quantification 
evaluation since the media contained the serum proteins which we did not intend to 
evaluate and would not be meaningful in terms of tumor cell exosome evaluation. 
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A Bio-Rad protein assay was used for protein quantification and a standard curve 
using bovine serum albumin (BSA) dilution series (2 µg/ml, 4 µg/ml, 6 µg/ml, 8 
µg/ml and 10 µg/ml) and UVmini-1240 spectrophotometer (Shimadzu) was made. 
Each sample was diluted 10 times and 3 µl of diluted sample was used for protein 
quantification. The same volume (3 µl) of each BSA dilution was used for making 
standard curve. All samples and the standards were read at 595 nm. 
 
4.4 TK1 enzymatic assay 
A [3 H]-dThd phosphorylation assay was chosen for the enzyme activity evaluation. 
The supernatant media before ultracentrifugation, supernatant media after centrifu-
gation and isolated exosomes were checked for TK1 enzyme activity. The reaction 
mixtures were prepared as follows: 
 
Table 2. Reaction mix contents for enzyme activity assay. 
 Final Conc. Stock Conc. x 1 reaction 
Tris pH 7.6 50 mM 1 mM 2 µl 
MgCl2  5 mM 1 mM 0.2 µl 
BSA 0.5 mg/ml 20 mg/ml 1 µl 
DTT 5 mM 100 mM 2 µl 
ATP 2 mM 200 mM 0.4 µl 
3H-dTd 0.8 µM 50 µM 0.64 µl 
dThd 10 µM 1 mM 0.4 µl 
H2O - - 33.36 µl 
Final Volume - - 40 µl 
 
 Firstly, a 0.1 % final Triton concentration was added to the samples, which were 
incubated on ice for 20-30 minutes. Thereafter, 40 µl of a reaction mixture and 20 
µl of each sample were mixed and incubated in a water bath at 37 °C for 30 minutes. 
During these 30 minutes, 10 µl of samples were taken in 4 time points ( 0, 10, 20 
and 30 minutes). The different time point samples were loaded on DEAE filtermat 
(PerkinElmer) and then dried for 20-30 minutes. The filtermats were washed with 
ammonia formate three times (total 18 minutes) and 2 minutes with distilled water 
on a shaking plate. Afterwards, each filtermat was put in the corresponding scintil-
lation tube adding 500 µl of the elution buffer (HCl 0.1 M + KCl 0.2 M) and shaken 
for 20 minutes for TK1 elution. Thereafter, 2 ml of scintillation buffer was added to 
each tube and shaken for 10 minutes. Finally, the emission counting was done by 
the liquid scintillation analyser (PerkinElmer, Tri-carb, 2810TR) and Quantsmart 
(TM) software. The enzyme activity results were imported to Microsoft excel 2016 
and TK1 activity in 1 ml of supernatant media and the specific enzyme activity 
(SEA) were calculated. 
 
 
4.5 TK1 presence proved by western blotting 
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Western blot is a protein detection technique which was used for TK1 detection in 
this project. The supernatant media samples before ultracentrifugation, supernatant 
media samples after ultracentrifugation and isolated exosomes were used for prov-
ing TK1 presence. Twenty µl of SDS loading buffer was added to 80 µl of each 
sample and incubated 10 minutes at 95 °C. Subsequently, 25 µl of the mixture was 
run on SDS-PAGE at 150V for 2 hours. The proteins on the gel were transferred to 
polyvinylidene difluoride (PVDF) membrane at 0.2A (max 100V) for 50 minutes. 
The membrane was blocked by BSA blocking buffer for an hour and incubated with 
mouse monoclonal anti-human TK1 antibody (Arocell AB, Uppsala, Sweden) as a 
primary antibody overnight and then was washed three times with TBST (tris-buff-
ered saline plus tween-20) for 30 minutes in total and once with tris-buffered saline 
(TBS) for 5 minutes. The membrane was incubated with the secondary anti-mouse 
antibody (LiCor bioscience, U.S) for an hour and washed again as previously de-
scribed. Finally, the membrane was developed by Odyssey® CLx Imaging System 
(LI-COR Biosciences, U.S.) in grey scale mood. 
  
4.6 TK1 presence proved by dot blot chemiluminescence 
assay 
Dot blotting, as a straight forward protein detection method was used for TK1 de-
tection in samples of this project. Dot blot is almost the same as western blot except 
it does not have the running and the transferring steps which makes it easier to op-
timize. Ten percent Triton was added to a sample up to 0.1% final concentration and 
incubated for 20-30 minutes on ice. Afterwards, the loading frame was put on top 
of a suitable size of nitrocellulose (NC) membrane then, 3 µl of samples were loaded 
on the NC membrane through the frame, 3 µl of 20 ng/3 µl, 10 ng/3 µl, 8 ng/3 µl, 6 
ng/3 µl, 4 ng/3 µl, 2 ng/3 µl, 1 ng/3 µl and 0.5 ng/3 µl of TK1 recombinant protein 
(made in house, (45)) as a positive control and 3 µl of PBS as a negative control. 
TK1 recombinant protein was used for quantification. Membranes were left to dry 
for 20 minutes and blocked with 10% milk blocking buffer for an hour followed 
incubation with a mouse monoclonal anti-human TK1 antibody (amino acids 161–
183, AYTKRLGTEKEVEVIGGADKYHS; MAB 528–2, AroCell AB, Uppsala, 
Sweden) overnight. The MAB 528–2 antibodies has been biotinylated using the 
ChromaLink™ Biotin Antibody Labeling Kit (Solulink, California, USA) according 
to manufacturer’s instructions (46). The membrane was washed firstly for 15 
minutes by TBS and then TBS for 5 additional minutes. Thereafter, the membrane 
was incubated with streptavidin-HRP antibody (Thermo Scientific, USA) for an 
hour and washed again as previously described. Detection reagents (Amersham™ 
ECL™ Western Blotting detection reagents, UK) and ChemiDoc™ Touch Imaging 
from Bio-Rad were used for developing and 4 images were captured in 120 seconds. 
ImageJ (version 1.52a) was used to quantify the TK1 concentration. 
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4.7 Statistical analysis 
For the comparison of TK1 activity of BJ-N cell samples and BJ-T cell samples and 
also TK1 concentration in BJ-N cell samples and BJ-T cell samples, a two-tailed 
distributed and unequal variance t-test was used for calculating the p-value. 
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5.1 Exosome isolation 
5.1.1 Optimizing stage 
The exosome pellet after ultracentrifugation (Fig. 3) was re-
suspended in 100 or 200 µl PBS and concentration factors 
were 250, 178.9 and 283 for OTEX1, OTEX2 and OTEX3 
samples respectively. 
 
5.1.2 BJ-T and BJ-N exosomes 
The exosome pellets of BJ-T cell and BJ-N were resus-
pended as previously described. There were six sets of sam-
ples and their concentration factors are shown in table 3.  
 
Table 3. Concentration factors in different BJ-N and BJ-T cells samples. 
Series number Sample name Concentration Factor 
1 NEX1 209.7 
TEX1 193 
2 NEX2 191.1 
TEX2 211.8 
3 NEX3 336.2 
TEX3 325 
4 NEX4 322.2 
TEX4 339.1 
5 NEX5 307.4 
TEX5 312.6 
6 NEX6 246.1 
TEX6 285.85 
 
 
5 Results 
Figure 3. Exosome pel-
let appearance after ul-
tracentrifugation 
(107,000 x g, 6 hours). 
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5.2 Protein quantification 
5.2.1 Optimizing stage 
Protein amounts of exosome samples of each optimizing steps were quantified in 
order for comparison. The quantification results are shown in table 4. Sample vol-
umes (3 µl), the dilution factors for protein quantification preparing (x10) and the 
concentration factors of ultracentrifugation were all considered in order to calculate 
the exosome protein concentration in 1 ml of cell supernatant media. 
 
Table 4. Protein quantification of BJ-T cells exosomes in different optimizing settings. 
Optimizing 
setting 
number 
Sample name Normalized 
Absorbance 
Protein Conc. (µg/ 
3µl) * 
Exosome 
protein 
Conc. 
(mg/ml) ** 
1 BJ-T cell exosome (OTEX1) 0.139 2.230 0.0297 
2 BJ-T cell exosome (OTEX2) 0.275 3.393 0.0632 
3 BJ-T cell exosome (OTEX3) 0.644 6.547 0.0771 
* 3 µl of prepared sample for protein quantification 
** 1 ml of cell supernatant media 
 
5.2.2 BJ-T and BJ-N exosomes 
BJ-N and BJ-T cells exosome protein in every six sets of samples were quantified 
(table 5). The protein concentration was calculated by considering the factors which 
are mentioned in the previous section. 
 
Table 5. Protein quantification of BJ-N and BJ-T exosome samples. 
Sample 
series 
Sample name Normal-
ized Ab-
sorbance 
Protein Conc. (µg/ 
3µl) * 
Exosome pro-
tein Conc. 
(mg/ml) ** 
1 BJ-N cell exosome (NEX1) 0.506 5.367 0.085 
BJ-T cell exosome (TEX1) 0.554 5.777 0.099 
2 BJ-N cell exosome (NEX2) 0.585 6.042 0.105 
BJ-T cell exosome (TEX2) 0.423 4.658 0.073 
3 BJ-N cell exosome (NEX3) 0.626 6.393 0.063 
BJ-T cell exosome (TEX3) 0.669 6.760 0.069 
4 BJ-N cell exosome (NEX4) 0.599 6.162 0.063 
BJ-T cell exosome (TEX4) 0.574 5.948 0.058 
5 BJ-N cell exosome (NEX5) 0.395 4.418 0.047 
BJ-T cell exosome (TEX5) 0.662 6.700 0.071 
6 BJ-N cell exosome (NEX6) 0.723 7.222 0.097 
BJ-T cell exosome (TEX6) 0.513 5.427 0.063 
* 3 µl of prepared sample for protein quantification 
** 1 ml of cell supernatant media 
 
The mean of the protein concentration for BJ-N exosome samples was 0.078 and 
was 0.072 for BJ-T exosome samples. The standard deviations (SD) in BJ-N and 
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BJ-T exosome samples were 0.022 and 0.014 respectively (supplementary table 1), 
a p-value of 0.266. 
5.3 TK1 enzyme activity 
5.3.1 Optimizing stage 
In the first setting, although it was run at 80,000 x g for 3 hours, there was still high 
TK1 activity in the supernatant media after ultracentrifugation. Therefore, it was 
decided to increase the centrifugation time, both ultracentrifugation time and the 
speed. The second round was run at 96,000 x g for 5 hours and the enzyme activity 
in the supernatant after ultracentrifugation decreased while TK1 activity in the exo-
some sample was more than doubled compared to the first setting. Thereafter, the 
third setting was decided to run at 107,000 x g for 6 hours in the ultracentrifugation 
with the same centrifugation setting as the second round. TK1 activity in the exo-
some sample increased even more than the second round. To make the comparison 
more accurate and clearer, TK1 activity per 1ml of the supernatant and specific TK1 
activity per 1mg of total exosome protein were calculated and summarized in table. 
6 (and visualized in Fig. 4). TK1 activity in the optimize setting 1 is 24.59, 21.09 
and 0.30 (p mol/min/ml of BJ-T cells supernatant) in TBU1, TAU1 and TEX1 sam-
ples respectively. The enzyme activity for optimize setting 2 was 19.51, 19.21 and 
0.97 (p mol/min/ml of BJ-T cells supernatant) in TBU2, TAU2 and TEX2 samples 
respectively. The last optimize setting, TK1 activity is 17.17, 20.98 and 1.22 (p 
mol/min/ml of BJ-T cells supernatant) in TBU3, TAU3 and TEX3 samples respec-
tively. The specific TK1 activity based on the total exosome protein amount was 
calculated only for exosome samples due to the fact that there are lots of protein in 
the media necessary for cell growth, which we were not interested in. Therefore, the 
comparison of exosome proteins would not be logical for the supernatant samples 
because of media containing proteins. Here, the specific TK1 activities in TEX1, 
TEX2 and TEX3 were 10.45, 15.51 and 15.86 (p mol/min/mg of total exosome pro-
tein) respectively. 
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Table 6. TK1 activity and specific TK1 activity of samples in different optimizing settings. 
Optimizing 
setting number 
Sample name TK1 Activity (p 
mol/min/ml) * 
Specific TK1 
Activity (p 
mol/min/mg) ** 
1 BJ-T cell supernatant before 
Ultracentrifugation (OTBU1) 
24.595 - 
BJ-T cell supernatant after 
Ultracentrifugation (OTAU1) 
21.091 - 
BJ-T cell exosome (OTEX1) 0.303 10.455 
2 BJ-T cell supernatant before 
Ultracentrifugation (OTBU2) 
19.513 - 
BJ-T cell supernatant after 
Ultracentrifugation (OTAU2) 
19.212 - 
BJ-N cell exosome (OTEX2) 0.977 15.517 
3 BJ-T cell supernatant before 
Ultracentrifugation (OTBU3) 
17.172 - 
BJ-T cell supernatant after 
Ultracentrifugation (OTAU3) 
20.984 - 
BJ-T cell exosome (OTEX3) 1.221 15.863 
* p mol/min/ml of cell supernatant media 
** p mol/min/mg of total exosome protein 
 
 
 
5.3.2 BJ-T and BJ-N supernatant (before and after ultracentrifugation) and 
exosomes 
TK1 activity evaluation was done on BJ-T and BJ-N cells supernatant media (before 
and after ultracentrifugation) and isolated exosomes at the same time. It was per-
formed on six sets of samples and all parameters here represents the average of six 
repeats. The detailed data of the repeats is provided in supplementary table. 2. The 
enzyme activity in 1 ml of supernatant and specific enzyme activity (SEA) per 1 mg 
of total exosome protein were calculated. Table. 7 and Fig. 5A shows the results. 
The mean TK1 activity in BJ-N cells supernatant before ultracentrifugation samples 
Figure 4. Exosome-derived TK1 activity of samples in different optimizing settings. Comparison of 
exosome-derived TK1 activity in 1 ml of tumor cell supernatant media(A). Comparison of specific 
exosome-derived TK1 activity in 1 mg of total tumor cells exosome protein(B). 
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(NBU) was 6.754 p mol/min/ml of supernatant while it is 22.997 p mol/min/ml of 
supernatant in TBU samples. The mean of TK1 activity in BJ-N and BJ-T cells su-
pernatant media after ultracentrifugation samples (NAU and TAU) were 4.072 and 
23.570 p mol/min/ml respectively. In exosome samples, the mean of TK1 activity 
in BJ-N isolated exosomes (NEX) was 0.06 p mol/min/ml while for BJ-T isolated 
exosomes (TEX) showed 0.944 p mol/min/ml of activity. The p-value was less than 
0.05 (P<0.05). The mean of TK1 SEA was 0.77 p mol/min/mg for NEX and 13.107 
for TEX.  
 
Table 7. TK1 activity and specific TK1 activity in BJ-N and BJ-T cell supernatant media (before and 
after ultracentrifugation) and exosome samples. 
Sample name Mean of TK1 
Activity (p 
mol/min/ml)* ± 
SEM 
Mean of Specific 
TK1 Activity (p 
mol/min/mg) ** 
Con-
fi-
dence 
level 
95% 
P-value 
BJ-N cell supernatant before 
Ultracentrifugation (NBU) 
6.754±2.94 - 7.56 0.0041 
BJ-N cell supernatant after 
Ultracentrifugation (NAU) 
4.072±0.92 - 2.36 0.0016 
BJ-N cell exosome (NEX) 0.060±0.01 0.77 0.036 0.00049 
BJ-T cell supernatant before 
Ultracentrifugation (TBU) 
22.997±3.24 - 8.33 0.0041 
BJ-T cell supernatant after 
Ultracentrifugation (TAU) 
23.570±3.39 - 8.71 0.0016 
BJ-T cell exosome (TEX) 0.944±0.11 13.107 0.29 0.00049 
*  p mol/min/ml of cell supernatant media 
** p mol/min/mg of total exosome protein 
  
 
Exosome-derived TK1 activity was 15.73 times more in BJ-T cells than BJ-N 
cells which was statistically significant (Fig. 5B). The specific TK1 activity in 1 mg 
exosome protein was 18.1 times more in BJ-T cells than BJ-N cells (Fig. 5C). 
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If the TK1 activity (p mol/min/ml) in samples before ultracentrifugation was 
considered as total TK1 activity in the supernatant, the proportion of specific TK1 
activity of NEX/ specific TK1 activity of NBU showed that the exosome-derived 
TK1 activity was 0.8% of total TK1 activity in BJ-N cells while this proportion in 
BJ-T cells was 4% (4.6 times more in BJ-T cells than BJ-N cells). Fig. 6 shows the 
proportion of exosome-derived TK1 activity to non-exosome-derived one. 
 
 
 
Figure 5. Comparison of TK1 activity of BJ-N cell supernatant before and after ultracentrifugation and exosome samples 
in 1 ml of supernatant media(A). Comparison of TK1 activity of BJ-N and BJ-T cells exosome samples in 1 ml of superna-
tant media(B). Comparison of specific TK1 activity of BJ-N and BJ-T exosomes in 1 mg of total exosome protein (C). 
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5.4 Western blotting 
 
In both the optimizing part and the real project, the samples were used also to screen 
for the presence of TK1 protein in the supernatant media before ultracentrifugation, 
supernatant media after ultracentrifugation and isolated exosomes. 
 
5.4.1 Optimizing stage 
The supernatant media of BJ-T cells before and after ultracentrifugation and the 
isolated exosomes were run in western blots for three experiments in the optimizing 
process (Fig. 7). In the first experiment, there were two weak bands for tumor cells 
supernatant media before and after ultracentrifugation, and also a fairly strong band 
for the tumor exosome sample (Fig. 7A). For the second experiment, there were no 
bands for tumor cells supernatant media before and after ultracentrifugation while 
there was a strong band for the tumor exosome sample (Fig. 7B). The last round of 
western blot in the optimizing process also showed no bands for the supernatant 
media before and after ultracentrifugation but a very weak band for the exosome 
sample (Fig. 7C). The western blot was run several times on three optimizing steps 
samples but the early results were not reproducible. 
Figure 6. Comparison of exosome-derived TK1 and non-exosome-derived TK1 activity in BJ-N cells (A) and 
BJ-T cells (B) based on TK1 activity in supernatant (p mol/min/ml). 
Proportional Comparison of TK1 activity in BJ-N cell
0.89%  Exosomic TK1 Activity
99.11%  Non-exosomic TK1 Activity
Proportional Comparison of TK1 activity in BJ-T cell
4.10%  Exosomic TK1 Activity
95.90%  Non-exosomic TK1 Activity
A 
B 
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5.4.2 BJ-T and BJ-N supernatant (before and after ultracentrifugation) and 
exosomes 
The BJ-N and BJ-T cell samples were run on SDS-PAGE several times and trans-
ferring to PVDF membranes but no bands were observed. We do not know why the 
western blot did not work in these cases and therefore a new approach using the dot 
blot was chosen as an alternative technique. 
5.5 Dot blot chemiluminescence assay  
5.5.1 optimizing stage 
Three sets of optimizing stage samples were run on one nitrocellulose membrane 
(Fig. 8). Samples of each optimizing step were run twice. The first row is the first 
optimize setting samples, the second row is the second optimize setting samples and 
the third row is the third optimize setting samples. TK1 recombinant protein in the 
fourth row was used in a dilution series to make TK1 quantification possible by 
making the standard curve afterwards. The last row is a positive control for TK1 
(cytosolic extract of BJ-T cells) which was loaded in duplicates as well as duplicates 
of PBS as a negative control. By using ImageJ software, the dot blot membrane 
results were quantified and TK1 concentrations were calculated (summarized in 
Figure 7. Western blot results of the optimizing steps with different centrifugation and ultracentrifuga-
tion settings. 
A 
B C 
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table. 8 and visualized in Fig. 9). The exosome TK1 concentration was 0.0259 ng/µl 
of supernatant media which increased to 0.0364 ng/µl in the second setting. TK1 
exosome concentration reached 0.0369 ng/µl in the third optimizing setting. Ther-
fore, the last optimizing setting showed the most concentrated TK1. 
 
 
 
Table 8. ImageJ TK1 concentration quantification for three optimizing settings. 
Optimizing 
setting number 
Sample name Conc. 
(ng/µl)* 
Final Conc. 
(ng/µl)** 
1 BJ-T cell supernatant before 
Ultracentrifugation (TBU1) 
0.363 0.363 
BJ-T cell supernatant after Ultracentrifugation 
(TAU1) 
0.349 0.349 
BJ-T cell exosome (TEX1) 6.478 0.0259 
2 BJ-T cell supernatant before 
Ultracentrifugation (TBU2) 
0.274 0.274 
BJ-T cell supernatant after Ultracentrifugation 
(TAU2) 
0.255 0.255 
BJ-N cell exosome (TEX2) 6.512 0.0364 
3 
 
 
 
BJ-T cell supernatant before 
Ultracentrifugation (TBU3) 
0.307 0.307 
BJ-T cell supernatant after Ultracentrifugation 
(TAU3) 
0.258 0.258 
BJ-T cell exosome (TEX3) 9.422 0.0369 
* ng/ µl of sample 
** ng/ µl of supernatant media 
 
 
 
TBU TBU TEX TBU TBU TEX 
Optimizing 1 
Optimizing 2 
Optimizing 3 
TK1 Recombinant  
20 ng 10 ng 8 ng 6 ng 4 ng 2 ng 1 ng 0.5 ng 
PC PC NC NC 
Repeat 1 Repeat 2 
Figure 8. Dot blot results of different optimizing settings. The first row is for the samples of the first 
optimizing setting, the second row represents the samples of the second optimizing setting and the third 
row shows the samples of third optimizing setting. TK1 recombinant protein was loaded in dilution series 
in the fourth row. Cytosolic BJ-T cells extract and PBS were loaded on the last row as a positive and 
negative control respectively. 
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5.5.2 BJ-T and BJ-N supernatant (before and after ultracentrifugation) and 
exosomes 
All six sets of samples which included BJ-N cell samples and BJ-T cell samples 
were used for dot blotting. Each sample set was run at least twice (Fig. 10). All 
sample sets results were used to calculate the mean of TK1 concentration 
(Supplementary Table. 3). The sample loading amount and concentration factor of 
ultracentrifugation was considered in the final concentration calculation. The results 
of TK1 quantification is summarized in Table. 9, Fig. 11 and 12. The t-test was done 
for evaluating the difference TK1 concentrations between NBU samples and TBU 
samples, NAU samples and TAU samples, NEX samples and TEX samples 
separately. The concentration of BJ-N cells exosome-derived TK1 was 0.013 ng/µl 
of supernatant media while BJ-T cell exosome-derived TK1 concentration was 
0.027 ng/µl.  
Figure 9. TK1 concentration comparison between BJ-T cells supernatant 
media before and after ultracentrifugation and exosome samples in three 
different optimizing settings. 
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Table 9. TK1 concentration in BJ-N and BJ-T cells supernatant before and after ultracentrifugation 
and exosome samples based on dot blot results and ImageJ analysis. 
Sample name  Mean of TK1 concentrtion 
(ng/µl) * ±SEM 
Confidence 
level 95% 
P-value 
BJ-N cell supernatant before 
Ultracentrifugation (NBU) 
0.292±0.084 0.218 0.981 
BJ-N cell supernatant after 
Ultracentrifugation (NAU) 
0.242±0.082 0.211 0.924 
BJ-N cell exosome (NEX) 0.013±0.001 0.005 0.020 
BJ-T cell supernatant before 
Ultracentrifugation (TBU) 
0.295±0.096 0.249 0.981 
BJ-T cell supernatant after 
Ultracentrifugation (TAU) 
0.230±0.090 0.232 0.924 
BJ-T cell exosome (TEX) 0.027±0.004 0.011 0.020 
* ng/µl of superntant media 
 
 
Figure 10. Dot blot results of one set of samples. every samples run twice (the first row is the first 
repeat and the second row is the second repeat). Each repeat has 6 samples including (from left to 
right) BJ-N cell supernatant media before ultracentrifugation (NBU), BJ-N cell supernatant media 
after ultracentrifugation (NAU), BJ-N exosome (NEX), BJ-T cell supernatant media before ultracen-
trifugation (TBU), BJ-T cell supernatant media after ultracentrifugation (TAU) and BJ-T exosome 
(TEX). TK1 recombinant protein was loaded in dilution series in the third row. Cytosolic BJ-T cells 
extract and PBS were loaded on the last row as a positive and negative control respectively. 
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 If the TK1 concentration in exosome samples was considered exosome-derived 
TK1 and the TK1 concentration in supernatant media samples after 
ultracentrifugation was considered non-exosomic derived TK1 (or TK1 from other 
source than exosomes), it could be possible to clarify the proportion of exosome-
derived TK1 to total TK1 (Fig. 13). Exosome-derived TK1 in BJ-T cells was 10.49% 
Figure 11. TK1 concentration comparison in BJ-T and BJ-N supernatant media before and after ultracentrif-
ugation and exosome samples. 
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Figure 12. TK1 concentration comparison in BJ-T and BJ-N exosome samples. 
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of the total TK1 however, exosome-derived TK1 in BJ-N cells was 5.25% of the 
total TK1.  
 
 
 
 
 
 
 
 
 
  
Figure 13. Comparison of the proportional concentration of exosome-derived TK1to non-exosome-
derived TK1 in BJ-N (A) and BJ-T cells (B). 
Proportional Comparison of TK1 in BJ-N cell
5.25%  Exosome-derived TK1
94.75%  Non-exosome-derived TK1
Proportional Comparison of TK1 in BJ-T cell
10.50%  Exosome-derived TK1
89.50%  Non-exosome-derived TK1
A 
B 
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The first step of this project was exosome isolation. Although there are different 
exosome isolation techniques such as size-based techniques, immunoaffinity 
capture-based techniques and exosome precipitation kits, which one to use was 
based on the purpose of the study. The ultracentrifugation-based technique is the 
gold standard for exosome isolation due to the fact that it is easy to use, it needs 
little technical expertise, is moderately time consuming and needs no or little sample 
pretreatment (47). The results of the optimizing stages showed that although the 
lowest speed and time of ultracentrifugation could isolate TK1-containing 
exosomes, increasing the low speed centrifugation time from half an hour to an hour, 
increasing the time of ultracentrifugation run from 3 hours to 6 hours in addition to 
increasing the speed from 80,000 x g to 107,000 x g could lead to an increase in 
TK1 concentration in the isolated exosome samples and a decrease in TK1 activity 
in the supernatant media after ultracentrifugation compare to the supernatant media 
before ultracentrifugation. It was shown previously that 100,000 x g for 3 hours 
could be sufficient for exosome isolation (48) but it was also shown in this project 
that increasing the time and speed of ultracentrifugation could increase the yield of 
TK1-containing exosomes. The enzyme activity in exosome samples increased 
during the optimizing process. TK1 activity per 1 ml of supernatant increased in 
exosome samples by increasing the time and speed of ultracentrifugation. The TK1 
activity decreased in the supernatant media samples after ultracentrifugation com-
pared to the supernatant media samples before ultracentrifugation. The specific ac-
tivity of TK1 per 1 mg of exosome protein was also increased gradually by increas-
ing the ultracentrifugation time and speed. Therefore, the last set up for exosome 
isolation was the most efficient one for this study. 
 Dot blot and western blot are similar techniques for specific protein evaluation. 
Dot blot is technically easier than western blot, while both methods have their own 
pros and cons. In the dot blot method, whole samples were loaded on the membrane 
and it is very unlikely to lose them in theblotting process. Therefore, it would be a 
good choice if the protein target is small or low in term of amount in the sample. 
6 Discussion and Conclusion 
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However if the antibody was not specific enough, unspecific binding to the primary 
antibody could occur. On the other hand, in western blotting by running the sample 
on the SDS-PAGE and separating different proteins based on their mass, the 
probability of unknown unspecific binding is decreased. It can also be considered 
that wet western blotting (which was used in this project) has the buffer based 
transferring step which can increase the probability of protein loss during the 
transferring step, particularly for the low abundant and small sizes proteins which 
can also make the optimization more time consuming and difficult (49,50). The 
initial western blot worked well (see Fig. 4) but for some unknown reasons it did 
not work later even though a lot of effort had been used to optimize the procedure. 
After trying to optimize the western blotting in this project, it was decided to 
utilize the dot blot as an alternative method for TK1 protein concentration 
determination. In the optimize steps, the exosome-derived TK1 concentration 
increase was also supported by dot blotting results. In the dot blot results, there were 
very weak circles (band/signal) for the tumor cells supernatant media before and 
after ultracentrifugation and a clear circle for the BJ-T exosome samples. The 
specific TK1 activity in the exosome sample of the third setting of optimization was 
slightly more than exosome samples of the second setting as well as the dot blot 
result showed that TK1 was a bit more concentrated in third setting than other 
settings. Furthermore, the protein quantifiction showed higher total protein amounts 
in the third optimizing setting which regardless of specific protein showed the 
highest exosome concentration in the exosome pellet of third optimizing setting. 
Therefore, the third setting was chosen for running both the normal and tumor 
samples of the current project.  
 The enzyme activity in 1 ml of supernatant was calculated since comparing the 
supernatant and the exosome samples could be possible, and specific enzyme activ-
ity in 1 mg of exosome protein was calculated for a more accurate comparison of 
normal cell exosomes and tumor cell exosomes. However, it could not be done for 
the supernatant media samples because the media contains many other proteins from 
the FBS, which it’s evaluation was not useful for this study. It was concluded that 
the exosome-derived TK1 was higher in BJ-T cells compared to BJ-N cells, which 
could mean that it might affect tumor formation and progression. 
 Western blot and dot blot techniques used in this study are routine methods for 
specific protein evaluation while there are some other methods that could be used as 
well, including immunoprecipitation, mass spectrometry (which could be used to 
determine all exosome content based on mass-to-charge ratio) (51). The enzyme 
activity evaluation could also be done via different approaches such as a TK-radio 
enzymatic assay (TK-REA), TK liaison assay or divitum assay based on the research 
purposes (17). The methods used in the current project were chosen as they were 
more accurate and available in the lab. 
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Wei Sun and colleagues claimed that the tumor cells produce and secret more 
total proteins, nucleic acids and lipids (52). This study showed that the total exosome 
protein concentration in BJ-N and BJ-T cells (NEX and TEX) were not significantly 
different (P-value>0.05) which means that the total excreted protein via exosomes 
in the normal and tumor cell culture are similar. Therfore, if there is any difference 
between the protein secretion of BJ-T cells and BJ-N cells, it is likey not to be related 
to exosome excretion, and could be due to other protein secretion pathways.  
However, the TK1 amount in NEX and TEX samples was significantly different (P-
value<0.05) and TK1 was 2 times more in BJ-T derived-exosomes than BJ-N 
derived-exosomes. The TK1 protein amount was not significantly different neither 
in NBU and TBU samples nor in NAU and TAU samples. The proportion of 
exosome-derived TK1 to total TK1 was calculated in both the BJ-N samples and the 
BJ-T samples. It showed that the proportion was 2 times more in BJ-T cells than BJ-
N cells which could associate with the nature of tumor cells but more in vitro 
investigations would have to be done to confirm this. So far, the results of this study 
support the literature behind the role of TK1 in various cancer types (31,33,35).  
It is well-established that the serum and tissue-derived TK1 correlate with the 
pathological stage and clinical signs in different cancer types, which were briefly 
described in 2.3 part of this thesis (TK1 as a biomarker in cancers) but they could 
not be directly compared to this study because the serum or tissue-derived TK1 is 
not comparable to the cancer cell cultured exosome-derived TK1. If we want to 
compare the serum, tissue and/or the cell cultured exosome-derived TK1,  tissue and 
blood could be collected from healthy individuals and cancer patients. The tissue 
could be cultured and exosomes extracted then isolated. Subsequently, TK1 from 
the serum-derived exosomes and cell cultured derived-exosomes could be 
compared. Roughly, our results support previous studies showing that BJ-T cells 
excrete more TK1 in the exosomes than BJ-N cells. Additionally, our study did not 
clarify the exosome number in BJ-T and BJ-N cells. For this purpose, electron 
microscopy and an exosome specific antibody such as CD63, CD81 and CD9 
antibody could be used. Moreover, these antibodies could be used as an exosome 
marker for the resuspended exosome pellets. The result could be more accurate 
when the exosome number of BJ-T cells and BJ-N cells are compared in parallel, as 
claimed by Jenjaroenpun and colleagues, where the number of exosomes appear 
higher in tumor cells than normal cells (53). It would be possible to see if either BJ-
T cells secrete much more TK1 than BJ-N cells with equal exosome numbers or BJ-
T cells secrete more TK1 in more total exosome number than BJ-N cells. To be more 
conclusive, the exosome number, total TK1 and exosome-derived TK1 could be 
evaluated in parallel, and separately in vitro and/or in vivo (in serum, cancer tissue 
and cultured cells).  
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 There are very few studies on exosome derived TK1 and its function, and this 
study could complement them in terms of how TK1 is excreted out of the cells. It 
has been shown that TK1 in plasma-derived exosomes is higher in breast cancer 
patients than normal cases, which supports our findings. Here,they claimed that TK1 
in plasma-derived exosomes could be an early breast cancer biomarker and also 
useful for choosing the treatment option (43). Furthermore, Dubois has studied 
prostasomes and evaluated different prostate cancer cell lines and compared 
exosome-derived TK1 from aforementioned cell lines (in part 2.6) with normal 
prostasomes, which were isolated from seminal fluid of healthy individuals (44). 
Dubois found that the exosomes of the most metastatic prostate cancer cell line 
(PC3) showed significantly higher TK1 Unit values compared to other cell lines’ 
exosomes and the healthy individuals prostasomes. However, there are some points 
to discuss about the studies methods and materials compared to our study. The 
samples used in that study were exosomes from different prostate cancer cell lines 
in terms of metastatic feature (PC3 is much more metastatic than LNCaP and DU1) 
as the tumor samples and the prostasomes from seminal fluid of the healthy persons. 
Technically, these two types of samples are not comparable due to their sources. 
Although cancer cell lines were originally collected from cancer patients, they are 
immortalized and also have different characteristics due to the culture conditions. 
The cancer cell lines were cultured in as similar conditions to the body as possible 
in laboratorie. However,  the microenvironment and the cell interactions of cancer 
cells in the culture condition is different from cancer cells in the human body. 
Therefore, the comparison of exosome-derived TK1 in the way that the study was 
done is fundamentally questionable.  
In our study, BJ-T cells and BJ-N cells as tumor and normal cells were used to 
make the comparison more logical. On the other hand, in our study, a [3 H]-dThd 
phosphorylation assay was used for TK1 activity evaluation, which directly 
measures TK1 activity in 37 °C (the natural temperature for TK1) while in Dubois 
study the TK1 real-time activity assay was more complicated. This method was de-
veloped around six years ago and indirectly measures the TK1 activity. The method 
is Taq DNA polymerase-based involving several other enzymes downstream of TK1 
reaction to produce dTTP, which is then used to generate the complement strand of 
an oligonucleotide template catalyzed by the Taq DNA polymerase (54). Although 
all the processes carried out at 37 °C where Taq DNA polymerase could act at this 
temperature (1.5 nucleotides/sec), the optimum temperature for its activity is 75-80 
°C (150 nucleotides/sec) (55,56). Therefore, the Taq DNA polymerase will act 
slowly and consequently dTTP accumulation may inhibit TK1 activity(57).  
 In this project, TK1 activity assay was performed to evaluate the rate of reaction 
of TK1 with thymidine but count per minute (CPM) could not be used alone to 
evaluate the TK1 protein amount. If ten times more CPM were seen in the tumor 
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cell exosome sample than the normal cells exosomes, it could not be easily 
concluded that the TK1 amount in the tumor cells exosome sample is ten times more 
than the normal cell exosomes since the relation of CPM and enzyme amount is not 
linear and depends on several factors like enzyme concentration, substrate 
concentration, temperature, time of reaction and pH. Therefore, CPM can only give 
a rough idea about the enzyme amount in the samples. By calculating the specific 
enzyme activity it would be possible to measure how much dTMP was produced in 
a time unit (minutes) in 1 mg of total protein, and then it could be possible to 
compare the TK1 amount in BJ-N exosomes and BJ-T exosome samples. 
 This study shows that there is much more exosome-derived TK1 in BJ-T cells 
than BJ-N cells, which may suggest that TK1 could have a role in the nature of 
tumor formation, growth and progression. More work is needed to investigate the 
role of exosome-derived TK1 in cancer using in vitro methods such as treating 
different normal and tumor cells with isolated exosomes, scratching assays and/or 
migration assays. It will be even more similar to the real tissue environment if 2D 
cell culture method could be replaced by 3D culture like the spheroid and organoid. 
Additionally, in vivo investigation could be complementary to see the tumor cells 
exosome effect on specific organs or whole body. Although exosome-derived TK1 
could associate with the formation or progression of cancer, exosomes contain other 
proteins, microRNA and other RNA types, which can have roles in the cancer 
occurrence and/or cancer progression, and different studies were done on exosome-
derived miRNAs and their role in different cancer (58). Another consideration is 
that the tumor exosome field is still so young in terms of understanding its biological 
and biochemical features as well as its role in tumor development, pathogenesis and 
its usage as a candidate for tumor diagnosis, therapy and prognosis. Thus, more 
studies are needed to gain precise information. 
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